Absci Corporation announced the appointment of Frans van Houten to its Board of Directors. With his exceptional leadership experience and deep industry knowledge in the healthcare and technology industries, van Houten will play a pivotal role in supporting Absci's strategic vision and growth trajectory. Frans van Houten is a highly regarded business executive with a remarkable track record of success.

During his tenure as CEO of Royal Philips, van Houten led the company's transformation into a global leader in health technology, overseeing a critical strategic transformation, resulting in a streamlined portfolio that propelled Philips to the forefront of innovative healthcare solutions combining medical devices with informatics platforms to improve patient outcomes and raise provider productivity. The transformation put Philips on a path of higher growth and profitability. In addition to his role at Absci, van Houten serves on the Board of Directors of Novartis, a leading global pharmaceutical company, and acts as an advisor to private equity companies.

Van Houten served in 2017 as Co-Chair at the World Economic Forum in Davos. Van Houten's ability to steer complex changes and nurture innovation aligns closely with Absci's ambitious growth strategy and its vision to reshape the future of biopharmaceutical discovery. During his leadership at Philips, van Houten emphasized innovation and advanced technologies, spearheading the development of connected, patient-centric solutions.

This focus seamlessly aligns with Absci's commitment to accelerating the pace of drug discovery through its revolutionary Integrated Drug Creation platform.